111 related articles for article (PubMed ID: 7756385)
21. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.
Möller P; Sun Y; Dorbic T; Alijagic S; Makki A; Jurgovsky K; Schroff M; Henz BM; Wittig B; Schadendorf D
Br J Cancer; 1998 Jun; 77(11):1907-16. PubMed ID: 9667667
[TBL] [Abstract][Full Text] [Related]
22. Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice.
Kishida T; Asada H; Itokawa Y; Yasutomi K; Shin-Ya M; Gojo S; Cui FD; Ueda Y; Yamagishi H; Imanishi J; Mazda O
Mol Ther; 2003 Nov; 8(5):738-45. PubMed ID: 14599806
[TBL] [Abstract][Full Text] [Related]
23. Immunologic therapy targeting metastatic melanoma: allovectin-7.
Chowdhery R; Gonzalez R
Immunotherapy; 2011 Jan; 3(1):17-21. PubMed ID: 21174553
[TBL] [Abstract][Full Text] [Related]
24. [Melanoma: surface markers as the first point of targeted delivery of therapeutic genes in multilevel gene therapy].
Pleshkan VV; Zinov'eva MV; Sverdlov ED
Mol Biol (Mosk); 2011; 45(3):416-33. PubMed ID: 21790004
[TBL] [Abstract][Full Text] [Related]
25. Genetically modified murine adipose-derived mesenchymal stem cells producing interleukin-2 favor B16F10 melanoma cell proliferation.
Bahrambeigi V; Ahmadi N; Salehi R; Javanmard SH
Immunol Invest; 2015; 44(3):216-36. PubMed ID: 25565576
[TBL] [Abstract][Full Text] [Related]
26. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study.
Kang WK; Park C; Yoon HL; Kim WS; Yoon SS; Lee MH; Park K; Kim K; Jeong HS; Kim JA; Nam SJ; Yang JH; Son YI; Baek CH; Han J; Ree HJ; Lee ES; Kim SH; Kim DW; Ahn YC; Huh SJ; Choe YH; Lee JH; Park MH; Kong GS; Park EY; Kang YK; Bang YJ; Paik NS; Lee SN; Kim SH; Kim S; Robbins PD; Tahara H; Lotze MT; Park CH
Hum Gene Ther; 2001 Apr; 12(6):671-84. PubMed ID: 11426466
[TBL] [Abstract][Full Text] [Related]
27. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.
de Vries IJ; Bernsen MR; Lesterhuis WJ; Scharenborg NM; Strijk SP; Gerritsen MJ; Ruiter DJ; Figdor CG; Punt CJ; Adema GJ
J Clin Oncol; 2005 Aug; 23(24):5779-87. PubMed ID: 16110035
[TBL] [Abstract][Full Text] [Related]
28. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
29. Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells.
Melani C; Chiodoni C; Arienti F; Maccalli C; Sule-Suso J; Anichini A; Colombo MP; Parmiani G
Nat Immun; 1994; 13(2-3):76-84. PubMed ID: 8173238
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy for melanoma.
Vaisrub S
JAMA; 1973 Sep; 225(10):1242. PubMed ID: 4542440
[No Abstract] [Full Text] [Related]
31. Gene delivery to the epidermis.
Trainer AH; Alexander MY
Hum Mol Genet; 1997; 6(10):1761-7. PubMed ID: 9300669
[TBL] [Abstract][Full Text] [Related]
32. New cancer therapy by immunomanipulation: development of immunotherapy for human melanoma as a model system.
Kawakami Y
Cornea; 2000 May; 19(3 Suppl):S2-6. PubMed ID: 10832714
[TBL] [Abstract][Full Text] [Related]
33. Immune and gene therapy for melanoma, and the immunobiology of melanoma.
Smith KJ; Skelton H
Int J Dermatol; 1999 Jul; 38(7):490-508. PubMed ID: 10440277
[No Abstract] [Full Text] [Related]
34. Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma.
Okada Y; Okada N; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T
Cancer Gene Ther; 2005 Jul; 12(7):608-16. PubMed ID: 15746944
[TBL] [Abstract][Full Text] [Related]
35. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
Russo V; Pilla L; Lunghi F; Crocchiolo R; Greco R; Ciceri F; Maggioni D; Fontana R; Mukenge S; Rivoltini L; Rigamonti G; Mercuri SR; Nicoletti R; Maschio AD; Gianolli L; Fazio F; Marchianò A; Florio AD; Maio M; Salomoni M; Gallo-Stampino C; Fiacco MD; Lambiase A; Coulie PG; Patuzzo R; Parmiani G; Traversari C; Bordignon C; Santinami M; Bregni M
Int J Cancer; 2013 Jun; 132(11):2557-66. PubMed ID: 23151995
[TBL] [Abstract][Full Text] [Related]
36. Is antigen specificity the key to efficient adoptive T-cell therapy?
Labarriere N; Khammari A; Lang F; Dreno B
Immunotherapy; 2011 Apr; 3(4):495-505. PubMed ID: 21463191
[TBL] [Abstract][Full Text] [Related]
37. Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells.
Sanchez-Perez L; Gough M; Qiao J; Thanarajasingam U; Kottke T; Ahmed A; Thompson JM; Maria Diaz R; Vile RG
Gene Ther; 2007 Jul; 14(13):998-1009. PubMed ID: 17443216
[TBL] [Abstract][Full Text] [Related]
38. Cancer therapy with genetically-modified T cells for the treatment of melanoma.
Lagisetty KH; Morgan RA
J Gene Med; 2012 Jun; 14(6):400-4. PubMed ID: 22610729
[TBL] [Abstract][Full Text] [Related]
39. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
[TBL] [Abstract][Full Text] [Related]
40. [Immunotherapy for melanoma: how can tolerance be overcome?].
Robert C
Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
